AZ-CAMELBACK-OWNER
16.3.2020 11:02:09 CET | Business Wire | Press release
One Can Imagine. That philosophy is the driving force of the experienced leadership team that’s responsible for introducing One Camelback, an innovative live-play community that’s taking shape at the hottest intersection in greater Phoenix, according to real estate and growth experts at Urban Land Institute.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200316005151/en/
“Arizona hasn’t seen anything quite like One Camelback – we expect this bold development to set a new benchmark for urban elegant living in the Southwest,” said Dale Phillips, President and Founder of Stellar Residential, the management company for One Camelback. “As one of the most ambitious construction transformations ever undertaken in Phoenix, this boutique, Class A development will deliver a vibrant use of residential space, with soaring and dramatic floor-to-ceiling views of Central Phoenix, modern and functional floorplans, upscale amenities and first-class services – all under one 11-story roof, while aesthetically adding some more glamour and elegance to the Phoenix skyline.”
As the iconic landmark undergoes a complete transformation, One Camelback will blend the finest there is in upscale sophisticated living with a range of exclusive, first-to-market retailers in the heart of Central Phoenix. It will be the first 1-Gigabit community, in Arizona through Cox Communications, which means each and every unit will have 1-Gigabit internet speeds included in the rent.
The 215,245-square-foot glass-ensconced property will include 163 first-class apartment units with exposed ceilings and 10 foot floor to ceiling windows. A selection of 16 different floorplans will be available, featuring upscale studio, 1-, 2-, and 3-bedroom apartments, all designed by Erwin Architecture. Additional exclusive residential amenities include a 6,500 square-foot rooftop terrace with a swimming pool, a swim-in place and endless pool for lap swimming or therapy, cabanas and a spa, as well as a yoga lawn deck and a lounge-style clubhouse. Residents will also have access to a secured underground garage with electric car-charging stations.
Capitalizing on its prime location, One Camelback is in negotiations to bring in highly sought-after, first-to-market upscale retailers to blend in with the historic neighborhood’s assortment of hip restaurants and trendy shops. Only walking distance from popular gourmet and specialty grocer AJ’s Fine Foods, One Camelback is also in close proximity to Uptown Plaza and light-rail transportation. The residences and retail spaces will be moments away from the downtown business core, major sporting event arenas, and the popular nightlife scene, serving residents by offering one of the best transit oriented developments known to the Valley.
With more than 143,000 people working within a 3-mile radius of its centralized location, One Camelback is located at the perfect triangle, connecting downtown Phoenix to the Biltmore area.
In March 2019, the construction efforts began with a glass-raising event to celebrate the start of the substantial transformation, from mortar and concrete to dramatic windows and high ceilings that will deliver soaring, bird’s eye views of Central Phoenix. The demolition of interior structures throughout the building was completed earlier this month, leaving a blank canvas for crews to make the vision for this iconic development come to a reality.
One Camelback is being developed by an affiliate of Sagamore Capital LLC, a Scottsdale-based investment firm, with financing arranged by Walker & Dunlop, and provided by Los Angeles-based ACORE Capital LLC. Katerra is acting as general contractor and a prime supplier for the project.
One Camelback is expected to be complete by 2021. More information is available by visiting OneCamelback.com or @LiveOneCamelback on Instagram.
About One Camelback
Situated at the hottest intersection in greater Phoenix, at the southeast corner of Central Ave. & Camelback Road, One Camelback will set a new standard in redefined upscale urban living. With its iconic glass exterior, extravagant residential units and amenities, first-class services and exclusive retail experiences, the boutique Class A development will deliver a highly desirable live-play lifestyle in a building that is expected to help redefine the Phoenix skyline. For more information about One Camelback, visit OneCamelback.com or @LiveOneCamelback on Instagram.
About Sagamore Capital LLC
One Camelback Owner LLC is an affiliate of Sagamore Capital LLC. In addition to One Camelback, Sagamore Capital and its affiliates currently have under development multifamily rental projects in Spokane, Washington, Brooklyn, New York, Jamaica (Queens), New York and Washington D.C., a student housing project in Pullman, Washington and a 14-unit condominium project in the Nolita area of Manhattan. It has been active in the Phoenix area with the successful acquisition and sale of student housing projects and two multifamily projects. Its affiliates are also investors in land developments located in Buckeye and Surprise.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200316005151/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom